ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 7109" data-attributes="member: 3"><p><strong>Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. <a href="http://link.springer.com/article/10.1007%2Fs11102-014-0563-z" target="_blank">http://link.springer.com/article/10.1007/s11102-014-0563-z</a> </strong></p><p></p><p></p><p>PURPOSE: Men with prolactin-secreting tumors usually harbor macroadenomas. The degree of pituitary dysfunction may vary among different adenoma size subgroups, as is recovery after treatment. Our study purpose was to characterize hypopituitarism and recovery after treatment in men with macroprolactinomas.</p><p></p><p></p><p>METHODS: A retrospective study, including a consecutive group of 81 men with pituitary macroadenomas (>/=10 mm) and hyperprolactinemia (>7xULN). Patients were divided into three categories according to adenoma size at presentation: 10-19 mm (group A), 20-39 mm (group B), and >/=40 mm (group C). We compared total testosterone, gonadotropins, cortisol, thyroid hormones and hemoglobin levels at presentation and after treatment.</p><p></p><p></p><p>RESULTS: Eighty-one patients were included; 24, 31 and 26 patients in groups A, B and C, respectively. Pretreatment hypogonadism prevalence was 75.0, 93.5 and 90.9 % (p = 0.046; A vs B and C), central hypocortisolism - 0, 6.9 and 33.3 % (p = 0.005), and central hypothyroidism - 6.7, 17.9 and 26.1 % (NS) in groups A, B and C, respectively. Only 26.7 % of all patients presented with hypocortisolism and/or hypothyroidism (42.9 % in group C). Anemia (Hb < 13.5 g %) was detected in 31.3, 57.1 and 80.0 % in groups A, B and C, respectively (p = 0.04). Larger adenoma diameter correlated strongly with lower FT4 levels following treatment (r = -0.42, p = 0.043).</p><p></p><p></p><p>CONCLUSIONS: Macroprolactinomas in men caused partial hypopituitarism, affecting testosterone in all adenoma size groups and cortisol more in patients with larger adenomas. However, most of the men did not have pituitary hormones affected, beside testosterone. Most patients recovered central hypocortisolism but not hypothyroidism following treatment.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 7109, member: 3"] [B]Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. [URL]http://link.springer.com/article/10.1007%2Fs11102-014-0563-z[/URL] [/B] PURPOSE: Men with prolactin-secreting tumors usually harbor macroadenomas. The degree of pituitary dysfunction may vary among different adenoma size subgroups, as is recovery after treatment. Our study purpose was to characterize hypopituitarism and recovery after treatment in men with macroprolactinomas. METHODS: A retrospective study, including a consecutive group of 81 men with pituitary macroadenomas (>/=10 mm) and hyperprolactinemia (>7xULN). Patients were divided into three categories according to adenoma size at presentation: 10-19 mm (group A), 20-39 mm (group B), and >/=40 mm (group C). We compared total testosterone, gonadotropins, cortisol, thyroid hormones and hemoglobin levels at presentation and after treatment. RESULTS: Eighty-one patients were included; 24, 31 and 26 patients in groups A, B and C, respectively. Pretreatment hypogonadism prevalence was 75.0, 93.5 and 90.9 % (p = 0.046; A vs B and C), central hypocortisolism - 0, 6.9 and 33.3 % (p = 0.005), and central hypothyroidism - 6.7, 17.9 and 26.1 % (NS) in groups A, B and C, respectively. Only 26.7 % of all patients presented with hypocortisolism and/or hypothyroidism (42.9 % in group C). Anemia (Hb < 13.5 g %) was detected in 31.3, 57.1 and 80.0 % in groups A, B and C, respectively (p = 0.04). Larger adenoma diameter correlated strongly with lower FT4 levels following treatment (r = -0.42, p = 0.043). CONCLUSIONS: Macroprolactinomas in men caused partial hypopituitarism, affecting testosterone in all adenoma size groups and cortisol more in patients with larger adenomas. However, most of the men did not have pituitary hormones affected, beside testosterone. Most patients recovered central hypocortisolism but not hypothyroidism following treatment. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top